<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 25-year-old woman was admitted after having had a <z:hpo ids='HP_0001945'>fever</z:hpo> for one month, <z:hpo ids='HP_0002315'>headache</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0001260'>dysarthria</z:hpo> and right-sided <z:hpo ids='HP_0001269'>hemiparesis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A 35-year-old man was admitted because of severe <z:hpo ids='HP_0000572'>loss of vision</z:hpo> and a history of <z:e sem="disease" ids="C0154870" disease_type="Disease or Syndrome" abbrv="">focal retinochoroiditis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Both were suffering from <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease can present with systemic symptoms that might be related to aberrant T-cell functions </plain></SENT>
<SENT sid="4" pm="."><plain>It is treated with a variety of immunoregulatory drugs </plain></SENT>
<SENT sid="5" pm="."><plain>Recently, treatment with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) alpha-inhibiting molecular designed drugs such as infliximab or etanercept has improved the therapeutic prospective of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet patients </plain></SENT>
<SENT sid="6" pm="."><plain>Both of the patients described above developed refractory disease and responded to treatment with these new drugs </plain></SENT>
</text></document>